2025-01197Notice

FDA Tackles Chemo's Cruel Side Effect: Permanent Nerve Damage

Published Date: 1/17/2025

Notice

Summary

The FDA just dropped a draft guide to help drug makers create treatments that prevent or ease nerve pain caused by chemotherapy, a tough side effect that can mess with cancer care. This affects patients battling cancer and companies developing new drugs, aiming to keep treatments on track and improve lives. Comments on this guide are open until March 18, 2025, so get your thoughts in and help shape the final rules!

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

FDA draft: Chemotherapy nerve-pain drugs

The FDA published a draft guidance to help drug and biologic sponsors develop products to prevent or treat chemotherapy-induced peripheral neuropathy (CIPN). The guidance gives recommendations on trial population, trial design, and selection of oncology-specific endpoints, and the public comment period is open until March 18, 2025. The notice also flags a safety concern that CIPN-mitigating drugs may reduce cancer treatment effectiveness or possibly promote tumor growth.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
1/17/2025

Department and Agencies

Department
Independent Agency
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register